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[Abstract] Mitochondrial dysfunction is associated with a number of human diseases. As an example, 
we recently established in vivo Drosophila models of IBMPFD (Inclusion body myopathy, Paget disease, 
and frontotemporal dementia), and uncovered that human disease mutations of the p97/VCP (Valosin 
Containing Protein) gene behave as hyperactive alleles associated with mitochondrial defects. 
Pharmacologic inhibition of VCP strongly suppressed disease and mitochondrial pathology in these 
animal models. In this protocol, we describe a method to evaluate mitochondrial respiratory function in 
IBMPFD patient-derived fibroblasts, as well as investigate the role of pharmacologic treatments. These 
experiments complement work done in animal models by investigating mitochondrial biology and the 
pharmacologic response in a human cell-based model of the disease. In principle, this technique can 
be used to investigate mitochondrial respiratory function for any disease in which patient-derived 
fibroblasts are available. 
Keywords: Patient-derived fibroblasts, Mitochondrial respiration, Seahorse XF assay, Inclusion body 
myopathy, Paget disease and frontotemporal dementia (IBMPFD), VCP/p97 
 
[Background] The mitochondrial electron transport chain (ETC) constitutes a series of protein 
complexes (complex I, II, III, IV and V) mediating the production of ATP coupled to the consumption of 
oxygen (O2). Briefly, the oxidation of nutrients (glucose, fatty acids, amino acids, etc.) by the organelle 
provides a pool of electrons which are sequentially transferred by ETC complexes between redox-active 
molecules located at the mitochondrial inner membrane, including ubiquinone, cytochrome c and O2. 
Early electron acceptors (e.g., ubiquinone, cytochrome c) are first reduced and then recycled to their 
oxidized forms, while O2, the terminal electron acceptor, is converted to H2O and not re-generated. For 
this reason, the net consumption rate of O2 (the Oxygen Consumption Rate or “OCR”) at complex IV 
serves as a proxy for mitochondrial ETC function in cells. 
  Measurement of the OCR in cultured cells has traditionally relied on detecting declines in the O2 levels 
in media surrounding cells. The advent of the Seahorse Extracellular Flux (Seahorse XF) analyzer has 
improved the throughput and sensitivity of these measurements, by allowing rapid and simultaneous 
measurements of the OCR from a small number of cells (typically, 5,000-100,000 cells per well) in an 
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adherent 24-well or 96-well format. In brief, the XF analyzer forms a transient microchamber consisting 
of a small volume (~2 μL) of media directly above the cell monolayer, and utilizes fluorescent probes to 
follow [O2] over time. For a more complete description of the principle of XF assays, see 
https://www.agilent.com/en/products/cell-analysis/how-seahorse-xf-analyzers-work. 
  Defects in mitochondrial ETC function directly underlie a set of genetic diseases affecting components 
of the ETC complexes (e.g., Leigh’s syndrome and others). In addition, mitochondrial ETC dysfunction 
can be indirectly associated with genetic diseases secondary to mutations in non-mitochondrial proteins, 
and potentially contribute to disease pathology in these settings. Assessment of mitochondrial ETC 
function in the disease setting has the potential to both implicate organelle dysfunction in the 
pathophysiology, as well as assess the impact of pharmacologic treatments. In this protocol, we describe 
the measurement of oxygen consumption rates in immortalized human fibroblasts derived from disease 
patients and age-matched controls. As a specific example, we consider disease-associated alleles of 
the p97/VCP gene. Missense mutations of p97/VCP are causative for inclusion body myopathy, Paget 
disease and frontotemporal dementia (IBMPFD) (Watts et al., 2004), a rare autosomal dominant disease 
associated with muscle weakness, bone pain and neurocognitive decline. VCP mutations are also 
associated with other neuropathic diseases [sporadic amyotrophic lateral sclerosis (ALS), hereditary 
spastic paraplegia and Charcot-Marie-Tooth 2 neuropathy] (Abramzon et al., 2012; de Bot et al., 2012; 
Gonzalez et al., 2014). The VCP gene encodes a highly conserved and abundant member of the AAA+ 
(ATPases associated with diverse cellular activities) protein family, which participates in multiple cellular 
processes, and potentially impacts mitochondrial biology (Meyer et al., 2012). Using in vivo IBMPFD 
models in Drosophila, we found that VCP disease mutants behave as hyperactive alleles, and cause 
significant mitochondrial defects including fragmentation and broken cristae. Feeding of VCP inhibitors 
relieve the pathology in these models (Zhang et al., 2017). To substantiate our findings in Drosophila, 
we investigated mitochondrial ETC function in IBMPFD cell-based models derived from patient 
fibroblasts. Disease-associated fibroblasts exhibited reduced oxygen consumption rates (as compared 
with age-matched controls), and were responsive to multi-day treatment regimens with VCP inhibitors 
(Zhang et al., 2017). Thus, the investigation of mitochondrial pathology present in animal disease 
models can be complemented by measurements of mitochondrial ETC function in a human cell-based 
model of the disease. 
 
Materials and Reagents 
 
1. Cell lines: human primary IBMPFD patient fibroblasts harboring the VCPR155H/+ mutation 
(GM21752) and age-matched controls (GM00024) were purchased from the Coriell Institute for 
Medical Research (https://catalog.coriell.org). Primary fibroblasts were immortalized by 
infection with retrovirus expressing hTERT. Infected cells were selected in puromycin (1.5 µg/ml) 
for 1 week and maintained in 1 µg/ml puromycin 
2. pBABE-puro-hTERT (Addgene plasmid, catalog number: 1771) 
3. Liquid DME medium (Sigma-Aldrich, catalog number: D6429) 
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4. Fetal Bovine Serum (Sigma-Aldrich, catalog number: F0926) 
5. Penicillin/Streptomycin (Sigma-Aldrich, catalog number: P0781) 
6. PBS (Sigma-Aldrich, catalog number: D8537) 
7. Trypsin-EDTA (Sigma Aldrich, catalog number: T4049) 
8. NMS-873 (Selleckchem, catalog number: S7285) 
9. ML240 (Sigma-Aldrich 1346527-98-7) 
10. DMSO (Sigma-Aldrich, catalog number: D8418) 
11. Seahorse XFe96 FluxPak (Agilent Technologies, catalog number: 102416-100), including 
sensor cartridge, calibration utility plate, 96-well culture plate, loading guides, calibrant solution 
12. Bicarbonate-free DMEM (Sigma-Aldrich, catalog number: D5030) 
13. L-glutamine (Sigma-Aldrich, catalog number: G7513) 
14. Sodium pyruvate (Sigma-Aldrich, catalog number: S8636) 
15. D-glucose (Sigma-Aldrich, catalog number: G8270) 
16. Oligomycin (Sigma-Aldrich, catalog number: O4876) 
17. CCCP (Sigma-Aldrich, catalog number: C2759) 
18. Antimycin A (Sigma-Aldrich, catalog number: A8674) 
19. Trichloroacetic Acid (Sigma-Aldrich, catalog number: T9159) 
20. Acetic Acid (Sigma-Aldrich, catalog number: A6283) 
21. Sulforhodamine B (SRB, Sigma-Aldrich, catalog number: 230162) 
22. Tris base (Sigma-Aldrich, catalog number: T1503) 
23. Culture media (see Recipe 1) 
24. Seahorse Assay Media (see Recipe 2) 
25. Stock solutions (see Recipe 3) 
a. 1 M glucose 
b. 200 mM glutamine  
c. 100 mM sodium pyruvate 
d. 50 mM Oligomycin 
e. 100 mM CCCP 
f. 50 mM Antimycin A 
g. Trichloroacetic Acid solution  
h. Acetic Acid solution  
i. Sulforhodamine B solution  
j. 10 mM Tris solution 
k. 1 mM NMS-873 stock solution 
l. 1 mM ML240 stock solution 
26. Bicarbonate-free DMEM medium (see Recipe 4) 
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Equipment 
 
1. Pipettes (0.5-10 μl, 2-20 μl, 20-200 μl, 100-1,000 μl) 
2. 8-channel multichannel pipettes (2-20 μl, 20-200 μl) 
3. Seahorse Biosciences Extracellular Flux Analyzer (Model: XF96 or XFe96) 
4. Hemocytometer (Hausser Scientific, catalog number: VWR 15170-168) 
5. 37 °C, non-CO2 humidified incubator (e.g., Seahorse PrepStation or equivalent) 
6. Plate reader for absorbance measurements (e.g., Tecan Infinite 200 or equivalent) 
 
Software 
 
1. WAVE (Agilent Technologies Seahorse Wave Desktop software, version 2.6 or equivalent) 
 
Procedure 
 
See Figure 1 for an overview of the complete protocol. The overall procedure involves plating human 
fibroblasts into a Seahorse XF96 cell culture plate at low density, followed by 4-6 days of 
pharmacological treatment. After treatment, a Seahorse XF assay is first run to collect data on 
oxygen consumption rates. After completion, cell quantities are normalized on a per well basis to 
account for differences in cell viability and growth. 
 
 
Figure 1. Timing and overview of protocol. On Day 1, cells are plated and allowed to attach 
overnight (Step 1). Drug treatment occurs for 4-6 days, starting on Day 2 (Step 2). A 6-day 
treatment is depicted in this figure. On the last day of treatment (Day 7), the Seahorse sensor 
cartridge is hydrated overnight (Step 3). The Seahorse assay is performed on Day 8 (Steps 4-
6). Cells are fixed after assay completion on Day 8, and normalization is performed on Days 8-
10 (Step 7). Step numbers refer to the main text. 
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1. Plate human fibroblasts into a Seahorse XF96 cell culture plate (Step 1) 
Note: Perform all steps using sterile technique. 
a. Pre-warm culture media, PBS, and Trypsin-EDTA solution to 37 °C. 
b. Wash adherent, cultured fibroblasts with PBS. Add trypsin-EDTA solution. Wait for cells to 
detach (3-5 min at 37 °C). Add an equal volume of culture media to neutralize trypsin. 
Resuspend cells in culture media/trypsin-EDTA mix, and transfer to a 15 ml conical tube. 
c. (Optional Step): Wash cells by pelleting cell suspension at 1,000 x g (5 min, 20 °C), 
removing supernatant, and resuspending the cell pellet in 2-3 ml of culture media. 
d. Count cells on a hemocytometer in triplicate. Resuspend cells at a final concentration of 
5,000 cells per 80 µl of culture media. 
e. Plate 80 µl of cell suspension per well into a Seahorse XFe96 cell culture plate. Leave the 
4 corners without cells (i.e., wells A1, A12, H1, H12 are filled with 80 μl of culture media with 
no cells). 
f. To promote even plating, let the culture plate sit for 30-60 min in the tissue culture hood 
without being disturbed. 
g. Transfer the plate to a 37 °C, 5% CO2 incubator overnight. 
2. Drug treatment (Step 2) 
Note: Perform all steps using sterile technique. 
a. Prepare fresh culture media containing drug (e.g., 1 nM NMS-873, 50 nM ML240) or vehicle 
(equivalent amount of DMSO). Prepare enough volume for 80 µl/well. 
b. With a vacuum, remove media from each well, and replace with fresh culture media 
containing drug or vehicle. 
c. Return plate to 37 °C, 5% CO2 incubator overnight. 
d. Repeat Steps 2a-2c every 24 h for the duration of the drug treatment (e.g., 4-6 days). 
3. Hydrate sensor cartridge and stabilize instrument (Step 3) 
Note: Perform one day prior to respiration measurements. 
a. Open a Seahorse XFe96 FluxPak. Remove the sensor cartridge (green), from the 96-well 
utility plate. 
Note: Make sure not to scratch the printed fluorophores on the sensor cartridge by placing 
the cartridge upside down on a flat surface. 
b. Using a 8-channel multichannel pipette, add 200 µl calibrant solution to each well of the 
utility plate. 
c. Carefully return sensor cartridge to the utility plate. Make sure not to scratch the 
fluorophores. 
d. Incubate Sensor cartridge and utility plate overnight in a 37 °C, non-CO2 incubator. 
e. Turn on Seahorse XF96 instrument and start up WAVE software. Ensure computer is 
connected to the instrument, and the temperature is set to 37 °C. Leave instrument on 
overnight to maintain temperature stability. 
4. Wash cells into Seahorse assay media (Step 4) 
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Note: Perform approximately 60 min prior to start of assay. 
a. Using a vacuum, remove media from each well of the Seahorse XFe96 culture plate. Using 
an 8-channel multi-channel pipette, add back 150 µl of warm Seahorse assay media. 
Repeat three times. 
b. On the last wash, remove as much media as possible, and add 150 µl of assay media. 
c. Place the plate in a 37 °C, non-CO2 incubator for approximately 60 min prior to 
measurements. 
5. Load cartridge with desired compounds (oligomycin, CCCP, antimycin A) (Step 5) 
Note: Final drug concentrations will be 5 µM oligomycin, 10 µM CCCP, and 1 µM antimycin A 
after each sequential injection. 
a. Prepare the following solutions (with drugs diluted from frozen stocks): 
2 ml of Seahorse assay media containing 80 µM oligomycin 
2 ml of Seahorse assay media containing 170 µM CCCP 
2 ml of Seahorse assay media containing 18 µM antimycin A 
b. Using a 2-20 µl multichannel pipette, load 10 µl of oligomycin solution into port A of each 
well. 
c. Using a 2-20 µl multichannel pipette, load 10 µl of CCCP solution into port B of each well. 
d. Using a 2-20 µl multichannel pipette, load 10 µl of antimycin A solution into port C of each 
well. 
e. Tap down sensor cartridge gently to ensure solution reaches bottom of each port. 
6. Run Assay (Step 6) 
a. Within the WAVE software, set up the following protocol: 
Calibration 
Equilibration 
Basal measurements: 4 cycles of Mix (3 min) and Measure (3 min) 
Injection (port A), followed by 4 cycles of Mix (3 min) and Measure (3 min) 
Injection (port B), followed by 4 cycles of Mix (3 min) and Measure (3 min) 
Injection (port C), followed by 4 cycles of Mix (3 min) and Measure (3 min) 
b. Start assay and insert sensor cartridge (loaded with drugs) into instrument on top of utility 
plate containing calibrant solution. Ensure no lids or drug loading guides are present. 
c. Allow instrument to calibrate (15-20 min). 
d. After the instrument has completed calibration, remove the utility plate and insert Seahorse 
XFe96 cell plate. Ensure no lids are present. 
7. Normalization (Step 7) 
Notes: 
a. Normalization of Seahorse data can be performed using multiple methods, including cell 
counting, cell staining, and protein measurements. Here, we describe a Sulforhodamine B 
staining protocol for normalization (Vichai et al., 2006), based on the ability of 
sulforhodamine B to bind protein-components present in fixed cells. 
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b. Use a multichannel pipette for each addition (#1-5) of the normalization process. 
1. After assay is complete, fix cells by adding 50% TCA solution directly to each well, to a final 
concentration of 10%. Incubate plate at 4 °C for 1-24 h. 
2. Wash cell culture plate 5 times with distilled water to completely remove all TCA solution. 
Dry plate completely (overnight at room temperature). 
3. Stain cells by adding 25 µl per well of SRB (Sulforhodamine B) solution. Incubate at room 
temperature for 30 min, with rocking. 
4. Wash plate 5 times with 1% acetic acid to remove any residual SRB. Dry plate completely 
(overnight at room temperature in the dark). 
5. Add 100 µl of 10 mM Tris solution per well to solubilize stain. Incubate plate at room 
temperature for 30 min with rocking. 
6. Measure absorbance at 510 nm, using a microplate reader. Signals for each well should be 
subtracted from absorbance signals for the background wells (A1, A12, H1, H12). 
Background-corrected absorbance values can be input into WAVE software to normalize 
rate measurements. 
7. Calculation of basal oxygen consumption rates (Basal OCR; Figure 2) is as follows: 
 
Basal OCR = Average OCR of 1st four measurements
− Average OCR of last four measurements 
 
The residual OCR (post injection of antimycin A) is considered the background or non-
mitochondrial OCR. 
8. Calculation of maximal oxygen consumption rates (Max OCR; Figure 2) is as follows: 
 
Max OCR = Max OCR value of four measurements following CCCP injections
− Average OCR of last four measurements 
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Figure 2. Schematic of sample oxygen consumption data. Normalized Oxygen consumption 
rates (OCRs) are plotted versus time over the course of a typical Seahorse experiment (Step 
6). Drugs (red) are injected at the indicated times, including oligomycin, CCCP, and antimycin 
A. Basal OCR and Maximal OCR are calculated as depicted (Step 7). Basal oxygen 
consumption rate (Basal OCR) is the average OCR of the first 4 measurements (prior to injection 
of oligomycin) minus the average OCR of the last 4 measurements (post injection of antimycin 
A). Maximal OCR is the max OCR of the four measurements post injection of CCCP minus the 
average OCR of the last 4 measurements (post injection of antimycin A). 
 
Recipes 
 
1. Culture media (DMEM + 10% FBS) 
445 ml Liquid DMEM 
50 ml Fetal Bovine Serum 
5 ml penicillin/streptomycin 
Filter/sterilize through a 0.2 µm filter into an autoclaved glass bottle 
Store at 4 °C 
Warm to 37 °C before use 
2. Seahorse Assay Media (prepare fresh on day of assay) 
8 ml of FBS (final concentration: 10%) 
0.8 ml of 1 M glucose (final concentration: 10 mM) 
0.8 ml of 200 mM glutamine (final concentration: 2 mM) 
0.8 ml of 100 mM pyruvate (final concentration: 1 mM) 
0.8 ml of penicillin/streptomycin (final concentration: 1%)  
68.8 ml of bicarbonate-free DMEM 
Warm solution to 37 °C, and adjust pH to 7.4 
Filter/sterilize through a 0.2 µm filter 
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Store at 37 °C until use 
3. Stock solutions 
a. 1 M glucose 
Dissolve in ddH2O 
Aliquot and store at -20 °C 
b. 200 mM glutamine  
Dissolve in ddH2O. Filter/sterilize through a 0.2 µm filter 
c. 100 mM sodium pyruvate 
Dissolve in ddH2O. Filter/sterilize through a 0.2 µm filter 
d. 50 mM Oligomycin 
Dissolve in DMSO, aliquot and store at -20 °C 
e. 100 mM CCCP 
Dissolve in DMSO, aliquot and store at -20 °C 
f. 50 mM Antimycin A 
Dissolve in DMSO, aliquot and store at -20 °C 
g. Trichloroacetic Acid solution 
50% (w/v)in ddH2O 
Note: Prepare fresh on the day of use, store at 4 °C. 
h. Acetic Acid solution  
1% (v/v) in ddH2O 
Store at room temperature in glass bottle 
i. Sulforhodamine B solution 
0.057% (w/v) in 1% acetic acid solution 
Store at 4 °C, in the dark 
j. 10 mM Tris solution 
pH 10.5 in ddH2O 
Store at room temperature 
k. 1 mM NMS-873 stock solution 
Dissolve in DMSO and store at -20 °C 
l. 1 mM ML240 stock solution 
Dissolve in DMSO and store at -20 °C 
4. Bicarbonate-free DMEM medium 
Dissolve 8.3 g powder in 1 L of ddH2O, filter-sterilize through a 0.2 µm filter 
Store at 4 °C 
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